NCT07189780

Brief Summary

Mid-to-low rectal cancer exhibits an extremely high incidence rate in China. Currently, the primary treatment approach for mid-to-low rectal cancer remains surgical intervention, with total mesorectal excision (TME) being the mainstream procedure. In male patients, Heald, Chi Pan , Wei Hongbo , and others have proposed different dissection techniques for the anterior rectal wall. Partial or complete preservation of Denonvilliers Fascia (DVF) during conventional TME (as proposed by Heald) has been shown to significantly reduce intraoperative bleeding and improve postoperative urodynamic function, urinary continence, and sexual function . However, these studies focused exclusively on male patients and did not include female subjects. In our previous research, we proposed that females do not possess an anatomical structure equivalent to the male DVF. Furthermore, compared to entering the dissection plane by incising the peritoneum 0.5-1 cm above the lowest point of the peritoneal reflection, initiating the peritoneal incision precisely at the lowest point of the peritoneal reflection better ensures the integrity of the mesorectum and vaginal structures, reduces intraoperative bleeding, provides a more favorable operative field, and avoids damage to physiological structures while ensuring complete tumor resection, thereby promoting postoperative recovery. Thus, we concluded that this plane represents the optimal surgical dissection plane for the anterior rectal wall during TME in female patients with mid-to-low rectal cancer without anterior wall invasion. Since our prior study combined anatomical and clinical retrospective research, we have initiated a prospective multicenter randomized controlled trial to further validate these clinical findings. This study aims to demonstrate that entering the dissection plane at the lowest point of the peritoneal reflection during mid-to-low rectal cancer surgery improves prognosis in female patients, providing high-level evidence-based medical support for the adoption of this technique and establishing the optimal surgical approach for female rectal cancer patients.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
52mo left

Started Oct 2025

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress12%
Oct 2025Aug 2030

First Submitted

Initial submission to the registry

September 17, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 24, 2025

Completed
7 days until next milestone

Study Start

First participant enrolled

October 1, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2027

Expected
2.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2030

Last Updated

September 24, 2025

Status Verified

September 1, 2025

Enrollment Period

1.9 years

First QC Date

September 17, 2025

Last Update Submit

September 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Estimated Blood Loss

    2-6hours

Study Arms (2)

Experimental Group

EXPERIMENTAL

Experimental Group:Entering the dissection plane by incising the peritoneum precisely at the lowest point of the peritoneal reflection.

Procedure: Surgical approach

Control Group

ACTIVE COMPARATOR

Control Group:Entering the dissection plane by incising the peritoneum 0.5-1 cm above the lowest point of the peritoneal reflection.

Procedure: Surgical approach

Interventions

Control Group:Incising the peritoneum 0.5-1 cm above the lowest point of the peritoneal reflection to enter the dissection plane. Experimental Group:Incising the peritoneum precisely at the lowest point of the peritoneal reflection (in the rectovesical or rectouterine pouch) to enter the dissection plane.

Control GroupExperimental Group

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Pathologically confirmed rectal adenocarcinoma.
  • Female patients scheduled to undergo laparoscopic total mesorectal excision (TME).
  • Body mass index (BMI) ≤ 30 kg/m².
  • Tumors with the distal margin located ≤ 10 cm from the anal verge.
  • Absence of distant metastases (e.g., to the liver, lungs, or other organs).

You may not qualify if:

  • Presence of severe pre-existing comorbidities (e.g., significant hepatic, renal, cardiac, pulmonary, or coagulation dysfunction).
  • History of malignancy in other organs.
  • Patients requiring emergency surgery due to conditions such as acute perforation or obstruction.
  • Intraoperative findings of tumor invasion into adjacent organs necessitating multivisceral resection or palliative resection.
  • Previous history of anorectal or rectal surgery. 6Preoperative magnetic resonance imaging (MRI) indicating invasion of the anterior rectal wall.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2025

First Posted

September 24, 2025

Study Start

October 1, 2025

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 1, 2030

Last Updated

September 24, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share